Advanced in Purpura

Marcel Reiser

Richard Wagner Str. 13-17, 
Koeln, NW, DE 
Advanced in Purpura
Richard Wagner Str. 13-17, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Marcel Reiser practices in Koeln, Germany. Mr. Reiser is rated as an Advanced expert by MediFind in the treatment of Purpura. His top areas of expertise are Secondary Immunodeficiency (SID), Adult Immune Thrombocytopenia, Sudden Infant Death Syndrome (SIDS), and Immune Thrombocytopenic Purpura (ITP).

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Purpura.

Gender
Male

Locations

Richard Wagner Str. 13-17, Koeln, NW 50674, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
View 1 Less Clinical Trial

36 Total Publications

Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.
Journal: European journal of haematology
Published: February 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Reiser's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile